|
 |
||||||||
 |
Commercialization Strategy Our commercialization strategy in the U.S. for ANX-530 (vinorelbine injectable emulsion), or Exelbine™, and ANX-514 (docetaxel lyophilized emulsion for injection) includes deploying an experienced, targeted sales force supported by an internal commercial infrastructure and seeking unique HCPCS product codes for Exelbine and ANX-514. Currently, we intend to build a commercial capability in the U.S. focused on Exelbine, as well as other products that we may develop, license or acquire, including ANX-514, should it be approved. We believe we can achieve our strategic goals by deploying an experienced sales force supported by an internal commercial infrastructure that targets community oncology practices and other organizations with defined characteristics, such as high vinorelbine use or an expected willingness to switch vinorelbine formulations. A key component to our commercial strategy in the U.S. for Exelbine and ANX-514 is to obtain unique Healthcare Common Procedure Coding System, or HCPCS, product codes that are distinct from those for Navelbine® and Taxotere®, respectively. If our products are provided unique HCPCS product codes, they will be reimbursed based on their own sales prices, without including sales prices of the applicable reference product or its generic competition. We believe this will provide greater freedom to price our products appropriately relative to competitive products, which may enhance their commercial value to us. |
